In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
January 25, 2011
In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
Sixty percent of survey participants with next-gen sequencers have an Illumina platform. Over the next 12 months, more than a third plan to bring in the HiSeq 2000, and more than a third the Ion Torrent PGM.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Sequencing Platforms Drive Choice, Competition, Lawsuits in 2010
January 4, 2011 / In Sequence - In Sequence Survey: Illumina Holds Two-Thirds of Sequencing Market, Splits Desktop Share with Ion PGM
October 2, 2012 / In Sequence - Survey: Illumina, SOLiD, and 454 Gain Ground in Research Labs; Most Users Mull Additional Purchases
January 19, 2010 / In Sequence - Survey Finds MiSeq, Ion PGM Tied for Most Likely Sequencing Purchase over Next 12 Months
April 24, 2012 / In Sequence - Survey Finds Researchers Most Likely to Purchase Ion Torrent PGM, MiSeq, HiSeq over Next Year
October 25, 2011 / In Sequence